Search Results

You are looking at 41 - 50 of 1,305 items for :

  • Refine by Access: All x
Clear All
Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Jordan D. Berlin, J. Michael Berry, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Eric Rohren, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, William Small Jr., Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

or presence of regional nodal metastasis. However, because initial therapy of anal cancer does not typically involve surgery, true lymph node status may not be determined accurately. Biopsy of inguinal nodes is recommended if tumor metastasis to these

Full access

Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli, and Pierre I. Karakiewicz

probability of survival for x additional years, given y years of accumulated survival. EFS time points used in the CS models consisted of from 1 year up to 10 years after surgery. Second, separate multivariable Cox regression (MCR) models predicting CSM

Full access

Siyana Kurteva, Robyn Tamblyn, and Ari Meguerditchian

of cancer patients having undergone surgery in Montreal (Quebec) to describe their post-discharge opioid use and identify potential patterns of unplanned health service use (ED visits, hospitalizations). Provincial health administrative claims were

Full access

Kimberly L. Johung and Stacey M. Stein

of epirubicin/cisplatin/fluorouracil (ECF) compared with surgery alone, 1 and the Intergroup 0116 trial showed a survival benefit with postoperative chemoradiation (CRT) to 45 Gy and concurrent fluorouracil and leucovorin. 2 More recently, the

Full access

Brian Badgwell

multidisciplinary clinical evaluation. This approach is not emphasized in regions of the world where a surgery-first approach is standard of care, radiation therapy is infrequently used, and many cancers are found at an early stage and don't require adjuvant

Full access

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty, and Barbara A. Goff

that they treat. In preparation for payment reform, ASCO developed a bundled payment model for the treatment of patients with cancer using chemotherapy. 2 , 3 Ovarian cancer is a complex disease requiring surgery and chemotherapy to achieve the best

Full access

David Scott Miller, Gini Fleming, and Marcus E. Randall

; 8 : 423 – 442 . 9 Morrow CP Bundy BN Homesley HD . Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study

Full access

Jaffer A. Ajani, James S. Barthel, Tanios Bekaii-Saab, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal Denlinger, Charles S. Fuchs, Hans Gerdes, James A. Hayman, Lisa Hazard, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, Michael Korn, Kenneth Meredith, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Mary Kay Washington, Christopher Willett, Douglas E. Wood, Cameron D. Wright, and Gary Yang

laparoscopic staging differ among various NCCN institutions. In some, laparoscopic staging is reserved for medically fit patients with potentially resectable disease, specifically when chemoradiotherapy or surgery is considered. In medically unfit patients

Full access

Joseph S. Friedberg

Performing surgery for malignant pleural mesothelioma “is like scraping paint off a wall: there is always going to be microscopic disease left,” declared Joseph S. Friedberg, MD, Chief of Thoracic Surgery at Penn Presbyterian Medical Center

Full access

Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang, and Zin Myint

Background: Non-metastatic muscle invasive bladder cancer (MIBC) is treated with radical cystectomy and survival is closely associated with final pathologic staging. For patients undergoing primary surgery there is evidence that delay > 90 days